ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements with these filters
ICRA assigned a new [ICRA]BBB (Stable) rating to Infinium Pharmachem's ₹52.20 Crore credit facilities. The assignment covers cash credit, term loans, and unallocated limits from ICICI Bank and SBI.
Infinium Pharmachem Limited held its 22nd Annual General Meeting on September 17, 2026. Shareholders transacted ordinary and special business, including director appointments and remuneration revisions.
Infinium Pharmachem Limited issued a postal ballot notice to seek shareholder approval for migrating its equity shares from the NSE Emerge platform to the main board.
Infinium Pharmachem Limited issued a notice for its Annual General Meeting to be held on September 17, 2026. The meeting agenda includes financial statement adoption and director re-appointments.
Infinium Pharmachem Limited has appointed M/s. Ronak R Jain & Associates as Internal Auditor and M/s. RTBR & Associates as Secretarial Auditor. The company also re-appointed BRS & Associates as Cost Auditor.
Infinium Pharmachem Limited has appointed an Internal Auditor, Secretarial Auditor, and Cost Auditor for the Financial Year 2026-27 to comply with statutory regulatory requirements.
Infinium Pharmachem's board approved migrating from the NSE SME platform to the Main Board, set the AGM date, and appointed new auditors for the upcoming fiscal year.
Infinium Pharmachem Limited has scheduled a board meeting for August 22, 2026, to discuss other business matters.
Infinium Pharmachem Ltd reported revenue from operations of ₹105.6 Cr (+45.3% YoY) and net profit of ₹6.5 Cr (+75.7% YoY) for H2 FY26.
Infinium Pharmachem reported a consolidated total income of ₹191.77 Crore for FY26. Net profit stood at ₹12.15 Crore, reflecting steady annual growth.
Infinium Pharmachem will hold a board meeting on May 29, 2026, to approve audited annual financial results. This update provides timeline visibility for shareholders.
Infinium Pharmachem resumed manufacturing operations following a revocation order from the Gujarat Pollution Control Board. The Sojitra facility recommenced regular production activities on May 20, 2026.
Infinium Pharmachem Limited reported a non-compliance regarding its Structural Digital Database for FY2026. A 17-day delay was observed in recording UPSI entries related to changes in key managerial personnel. The company has since revised its internal SOPs to mandate same-day entry for all UPSI events.
Infinium Pharmachem received a GPCB directive for the temporary closure of its Sojitra plant due to unauthorized waste disposal. The company must submit a ₹0.02 Crore bank guarantee. While production is halted, the company intends to maintain turnover for April 2026 by selling existing finished goods inventory.
Infinium Pharmachem Limited clarified exchange queries regarding its FY25 financial results. The company provided a chartered accountant's certificate confirming the utilization of ₹42.00 Crore from public and preferential issue proceeds. It also clarified that segment-wise reporting is not applicable as it operates in a single business segment.
Infinium Pharmachem Limited submitted a compliance certificate confirming that all shares remain in dematerialised form. No rematerialisation requests were received for the quarter ended March 31, 2026. This is a routine regulatory update with no material impact on business operations or financials.